UCLA MedTech and Digital Health Regulatory Study

RAPS members are invited to participate in a new independent IRB-exempt research initiative led by the UCLA Biodesign Hub for MedTech and Digital Health. The global study aims to understand industry perspectives on regulation and reimbursement policy, along with the resources and costs required to bring transformational medical technologies and digital health products through pre-regulatory, regulatory, and reimbursement milestones.

The researchers are interviewing founders, leaders and regulatory executives at venture-backed companies with an FDA-approved product under CDRH to examine trends, establish benchmarks, and inform future decision-making on regulatory, reimbursement, and innovation policy. All interviews are anonymous, confidential, and will only be reported in aggregate. Visit www.medtechstudy.com to learn more.

To participate in this study, click the "Sign Up Today!" button (this button will only display after you've logged in) and an email with instructions will be sent to you.